NBY logo

NovaBay Pharmaceuticals (NBY) EBITDA

Annual EBITDA

-$4.80 M
+$2.40 M+33.31%

December 1, 2023

Summary

Performance

1-Year Change

+33.31%

3-Year Change

+24.71%

5-Year Change

+36.88%

15-Year Change

+33.48%

NBY EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

73.29%
NBY annual EBITDA is higher than 73.29% of companies in Healthcare sector

High & Low

All-time High

$3.11 M
NBY annual EBITDA is currently -254.19% below its historical high of $3.11 million

3-Year Low

-$8.74 M

Earnings dates

Last Annual Earnings Report Date

Dec 1, 2023
NBY previous annual earnings announcement was published on Dec 1, 2023

Next Annual Earnings Report Date

N/A
NBY next annual earnings announcement has not yet been scheduled

OtherNBYprofitabilitymetrics:

Annual Revenue

$14.73 M
NBY annual revenue is $14.73 million

Annual Net Income

-$9.64 M
NBY annual net profit is -$9.64 million

Annual EBIT

-$5.00 M
NBY annual earnings before interest & taxes is -$5.00 million

Annual EPS

-$138.60
NBY annual earnings per share is -$138.60

Quarterly EBITDA

-$979.00 K
+$127.00 K+11.48%

September 1, 2024

Summary

Performance

3-Month Change

+11.48%

1-Year Change

-62.35%

3-Year Change

+8.85%

5-Year Change

+8.85%

NBY Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

69.24%
NBY quarterly EBITDA is higher than 69.24% of companies in Healthcare sector

High & Low

All-time High

$3.54 M
NBY quarterly EBITDA is currently -127.66% below its historical high of $3.54 million

3-Year Low

-$3.11 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 1, 2024
NBY previous earnings announcement was published on Sep 1, 2024

Next Quarterly Earnings Report Date

N/A
NBY next earnings announcement has not yet been scheduled

OtherNBYprofitabilitymetrics:

Quarterly Revenue

$2.44 M
NBY quarterly revenue is $2.44 million

Quarterly Net Income

-$1.21 M
NBY quarterly net profit is -$1.21 million

Quarterly EBIT

-$1.07 M
NBY quarterly earnings before interest & taxes is -$1.07 million

Quarterly EPS

-$0.60
NBY quarterly earnings per share is -$0.60

TTM EBITDA

-$6.46 M
-$376.00 K-6.18%

September 1, 2024

Summary

Performance

3-Month Change

-6.18%

1-Year Change

-15.93%

3-Year Change

-21.71%

5-Year Change

-21.71%

NBY TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

68.56%
NBY TTM EBITDA is higher than 68.56% of companies in Healthcare sector

High & Low

All-time High

$3.12 M
NBY TTM EBITDA is currently -306.95% below its historical high of $3.12 million

3-Year Low

-$9.68 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 1, 2024
NBY previous earnings announcement was published on Sep 1, 2024

Next Quarterly Earnings Report Date

N/A
NBY next earnings announcement has not yet been scheduled

OtherNBYprofitabilitymetrics:

TTM Revenue

$13.84 M
NBY TTM revenue is $13.84 million

TTM Net Income

-$10.12 M
NBY TTM net profit is -$10.12 million

TTM EBIT

-$6.75 M
NBY TTM earnings before interest & taxes is -$6.75 million

TTM EPS

-$35.80
NBY TTM earnings per share is -$35.80

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$4.80 M
NBY annual EBITDA is -$4.80 million

Annual Net Income

-$9.64 M
NBY annual net profit is -$9.64 million

Annual Interest Expense

-
NBY annual interest expense value is unknown

Annual Income Tax

-
NBY annual income tax value is unknown

Annual D&A

$203.00 K
NBY annual depreciation & amortization is $203.00 thousand

NBY EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+33.3%-62.4%-15.9%
3 y3 years+24.7%+8.8%-21.7%
5 y5 years+36.9%+8.8%-21.7%

NBY EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+45.1%-189.6%+68.5%-36.3%+33.2%
5 y5-yearat high+48.6%-189.6%+68.5%-36.3%+33.2%
alltimeall time-254.2%+77.1%-127.7%+84.3%-306.9%+69.2%

NovaBay Pharmaceuticals EBITDA History

DateAnnualQuarterlyTTM
Sep 2024
-
-$979.00 K(-11.5%)
-$6.46 M(+6.2%)
Jun 2024
-
-$1.11 M(-58.2%)
-$6.09 M(+0.5%)
Mar 2024
-
-$2.65 M(+52.6%)
-$6.05 M(+27.7%)
Dec 2023
-$4.80 M(-33.3%)
-$1.73 M(+187.4%)
-$4.74 M(-14.9%)
Sep 2023
-
-$603.00 K(-43.9%)
-$5.58 M(+5.0%)
Jun 2023
-
-$1.07 M(-19.4%)
-$5.31 M(-15.3%)
Mar 2023
-
-$1.33 M(-48.1%)
-$6.27 M(-12.9%)
Dec 2022
-$7.20 M(-17.7%)
-$2.57 M(+659.2%)
-$7.20 M(-7.0%)
Sep 2022
-
-$338.00 K(-83.4%)
-$7.74 M(-20.0%)
Jun 2022
-
-$2.03 M(-10.1%)
-$9.68 M(+1.9%)
Mar 2022
-
-$2.26 M(-27.2%)
-$9.49 M(+8.6%)
Dec 2021
-$8.74 M(+37.1%)
-$3.11 M(+36.5%)
-$8.74 M(+18.4%)
Sep 2021
-
-$2.28 M(+23.2%)
-$7.38 M(+3.2%)
Jun 2021
-
-$1.85 M(+22.3%)
-$7.16 M(+12.4%)
Mar 2021
-
-$1.51 M(-13.5%)
-$6.37 M(-0.2%)
Dec 2020
-$6.38 M(-31.7%)
-$1.75 M(-14.8%)
-$6.38 M(-6.9%)
Sep 2020
-
-$2.05 M(+93.9%)
-$6.85 M(+5.5%)
Jun 2020
-
-$1.06 M(-30.5%)
-$6.50 M(-4.5%)
Mar 2020
-
-$1.52 M(-31.6%)
-$6.80 M(-27.1%)
Dec 2019
-$9.34 M(+22.7%)
-$2.22 M(+31.2%)
-$9.34 M(+7.6%)
Sep 2019
-
-$1.70 M(+24.4%)
-$8.68 M(-0.3%)
Jun 2019
-
-$1.36 M(-66.4%)
-$8.70 M(-6.8%)
Mar 2019
-
-$4.05 M(+159.2%)
-$9.33 M(+22.7%)
Dec 2018
-$7.61 M(+5.4%)
-$1.56 M(-8.9%)
-$7.61 M(+35.6%)
Sep 2018
-
-$1.72 M(-14.0%)
-$5.61 M(-7.2%)
Jun 2018
-
-$2.00 M(-14.2%)
-$6.04 M(+4.5%)
Mar 2018
-
-$2.33 M(-637.4%)
-$5.78 M(-19.8%)
Dec 2017
-$7.22 M(-33.6%)
$433.00 K(-120.1%)
-$7.22 M(-25.3%)
Sep 2017
-
-$2.15 M(+23.7%)
-$9.66 M(+1.3%)
Jun 2017
-
-$1.74 M(-53.7%)
-$9.54 M(-4.7%)
Mar 2017
-
-$3.76 M(+86.6%)
-$10.02 M(-7.8%)
Dec 2016
-$10.87 M(-48.2%)
-$2.01 M(-0.8%)
-$10.87 M(-27.9%)
Sep 2016
-
-$2.03 M(-8.3%)
-$15.08 M(-17.8%)
Jun 2016
-
-$2.21 M(-52.0%)
-$18.36 M(-12.4%)
Mar 2016
-
-$4.61 M(-26.0%)
-$20.96 M(-0.0%)
Dec 2015
-$20.97 M
-$6.23 M(+17.4%)
-$20.97 M(+6.9%)
Sep 2015
-
-$5.31 M(+10.1%)
-$19.63 M(+6.7%)
DateAnnualQuarterlyTTM
Jun 2015
-
-$4.82 M(+4.3%)
-$18.39 M(+6.4%)
Mar 2015
-
-$4.62 M(-5.3%)
-$17.28 M(+3.7%)
Dec 2014
-$16.67 M(+9.9%)
-$4.88 M(+19.9%)
-$16.67 M(+0.5%)
Sep 2014
-
-$4.07 M(+9.5%)
-$16.58 M(+7.6%)
Jun 2014
-
-$3.71 M(-7.3%)
-$15.42 M(-2.3%)
Mar 2014
-
-$4.01 M(-16.4%)
-$15.77 M(+4.0%)
Dec 2013
-$15.17 M(+90.4%)
-$4.79 M(+65.1%)
-$15.17 M(+15.5%)
Sep 2013
-
-$2.90 M(-28.7%)
-$13.14 M(+28.1%)
Jun 2013
-
-$4.07 M(+19.5%)
-$10.26 M(+14.2%)
Mar 2013
-
-$3.41 M(+23.5%)
-$8.98 M(+12.7%)
Dec 2012
-$7.97 M(+104.5%)
-$2.76 M(>+9900.0%)
-$7.97 M(+5.2%)
Sep 2012
-
-$24.00 K(-99.1%)
-$7.57 M(-2.8%)
Jun 2012
-
-$2.79 M(+16.6%)
-$7.79 M(+75.0%)
Mar 2012
-
-$2.39 M(+1.3%)
-$4.45 M(+14.3%)
Dec 2011
-$3.90 M(-4.7%)
-$2.36 M(+872.8%)
-$3.90 M(+162.5%)
Sep 2011
-
-$243.00 K(-144.3%)
-$1.48 M(-46.6%)
Jun 2011
-
$549.00 K(-129.9%)
-$2.78 M(-37.0%)
Mar 2011
-
-$1.84 M(-3929.2%)
-$4.42 M(+8.0%)
Dec 2010
-$4.09 M(-231.4%)
$48.00 K(-103.1%)
-$4.09 M(+584.9%)
Sep 2010
-
-$1.54 M(+41.9%)
-$597.00 K(-162.8%)
Jun 2010
-
-$1.08 M(-28.2%)
$950.00 K(-48.5%)
Mar 2010
-
-$1.51 M(-142.7%)
$1.84 M(-40.9%)
Dec 2009
$3.11 M(-137.9%)
$3.54 M(>+9900.0%)
$3.12 M(-213.3%)
Sep 2009
-
$7000.00(-103.7%)
-$2.76 M(-31.8%)
Jun 2009
-
-$190.00 K(-18.8%)
-$4.04 M(-33.1%)
Mar 2009
-
-$234.00 K(-90.0%)
-$6.04 M(-29.6%)
Dec 2008
-$8.21 M(+44.1%)
-$2.34 M(+83.2%)
-$8.58 M(+10.7%)
Sep 2008
-
-$1.28 M(-41.7%)
-$7.75 M(-3.8%)
Jun 2008
-
-$2.19 M(-20.9%)
-$8.05 M(+7.6%)
Mar 2008
-
-$2.77 M(+83.8%)
-$7.48 M(+31.5%)
Dec 2007
-$5.69 M(+4.4%)
-$1.51 M(-4.6%)
-$5.69 M(-42.6%)
Sep 2007
-
-$1.58 M(-2.7%)
-$9.92 M(+22.0%)
Jun 2007
-
-$1.62 M(+65.5%)
-$8.13 M(+25.0%)
Mar 2007
-
-$981.00 K(-82.9%)
-$6.51 M(+17.8%)
Dec 2006
-$5.45 M(+54.8%)
-$5.73 M(-2856.7%)
-$5.53 M(-2756.7%)
Sep 2006
-
$208.00 K
$208.00 K
Dec 2005
-$3.52 M(+269.5%)
-
-
Dec 2003
-$953.00 K
-
-

FAQ

  • What is NovaBay Pharmaceuticals annual EBITDA?
  • What is the all time high annual EBITDA for NovaBay Pharmaceuticals?
  • What is NovaBay Pharmaceuticals annual EBITDA year-on-year change?
  • What is NovaBay Pharmaceuticals quarterly EBITDA?
  • What is the all time high quarterly EBITDA for NovaBay Pharmaceuticals?
  • What is NovaBay Pharmaceuticals quarterly EBITDA year-on-year change?
  • What is NovaBay Pharmaceuticals TTM EBITDA?
  • What is the all time high TTM EBITDA for NovaBay Pharmaceuticals?
  • What is NovaBay Pharmaceuticals TTM EBITDA year-on-year change?

What is NovaBay Pharmaceuticals annual EBITDA?

The current annual EBITDA of NBY is -$4.80 M

What is the all time high annual EBITDA for NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals all-time high annual EBITDA is $3.11 M

What is NovaBay Pharmaceuticals annual EBITDA year-on-year change?

Over the past year, NBY annual EBITDA has changed by +$2.40 M (+33.31%)

What is NovaBay Pharmaceuticals quarterly EBITDA?

The current quarterly EBITDA of NBY is -$979.00 K

What is the all time high quarterly EBITDA for NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals all-time high quarterly EBITDA is $3.54 M

What is NovaBay Pharmaceuticals quarterly EBITDA year-on-year change?

Over the past year, NBY quarterly EBITDA has changed by -$376.00 K (-62.35%)

What is NovaBay Pharmaceuticals TTM EBITDA?

The current TTM EBITDA of NBY is -$6.46 M

What is the all time high TTM EBITDA for NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals all-time high TTM EBITDA is $3.12 M

What is NovaBay Pharmaceuticals TTM EBITDA year-on-year change?

Over the past year, NBY TTM EBITDA has changed by -$888.00 K (-15.93%)